University of Kansas

Introduction

University Of Kansas is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<table class="infobox infobox-institution"> [@nih2024]
<tr><th colspan="2" class="infobox-header">University of Kansas</th></tr> [@research2024]
<tr><td colspan="2" class="infobox-image">🏛️</td></tr> [@pubmedindexed]
<tr><th class="label">Location</th><td>Lawrence, Kansas, USA</td></tr>
<tr><th class="label">Type</th><td>Public Research University</td></tr>
<tr><th class="label">Founded</th><td>1866</td></tr>
<tr><th class="label">Website</th><td>https://www.ku.edu</td></tr>
<tr><th class="label">Medical Center</th><td>Kansas City, Kansas</td></tr>
</table>

Overview

Introduction

University Of Kansas is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<table class="infobox infobox-institution"> [@nih2024]
<tr><th colspan="2" class="infobox-header">University of Kansas</th></tr> [@research2024]
<tr><td colspan="2" class="infobox-image">🏛️</td></tr> [@pubmedindexed]
<tr><th class="label">Location</th><td>Lawrence, Kansas, USA</td></tr>
<tr><th class="label">Type</th><td>Public Research University</td></tr>
<tr><th class="label">Founded</th><td>1866</td></tr>
<tr><th class="label">Website</th><td>https://www.ku.edu</td></tr>
<tr><th class="label">Medical Center</th><td>Kansas City, Kansas</td></tr>
</table>

Overview

The University of Kansas (KU) is the state's flagship research university with a strong commitment to neuroscience and neurodegeneration research. The University of Kansas Medical Center in Kansas City houses the Alzheimer's Disease Center and the Frontiers in Alzheimer's Disease Research program, making it a major hub for neurodegenerative disease research in the Midwest. KU researchers focus on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutics for Alzheimer's disease, Parkinson's disease, and related disorders.

History

Founded in 1866, the University of Kansas has grown to become a major research institution. The KU Medical Center was established in 1905, and the Alzheimer's Disease Center was designated by the National Institute on Aging in 2014. The center has since become a regional leader in Alzheimer's research, clinical trials, and patient care.

Research Focus Areas

KU researchers focus on multiple aspects of neurodegeneration:

Alzheimer's Disease Research

• Amyloid Biology: Studies on [APP](/entities/app-protein) processing, [Aβ](/proteins/amyloid-beta) aggregation mechanisms, and therapeutic antibodies
• [Tau](/proteins/tau) Pathology: Investigation of [tau](/proteins/tau) phosphorylation, spread, and therapeutic targeting
• Biomarkers: Development of CSF and blood biomarkers for early detection
• Clinical Trials: Participation in multicenter trials for disease-modifying therapies

Neurobiology of Aging

• Cellular and molecular mechanisms of brain aging
• Synaptic dysfunction in aging
• Metabolic changes in aged [neurons](/entities/neurons)
• Cognitive decline prevention strategies

Drug Discovery

• Novel therapeutic compounds for neurodegenerative diseases
• High-throughput screening for disease-modifying drugs
• Repurposing existing drugs for new indications
• Target validation and mechanism of action studies

Parkinson's and Movement Disorders

• [Alpha-synuclein](/proteins/alpha-synuclein) biology and therapeutics
• Neuroprotection strategies
• Lewy body disease research
• Deep brain stimulation outcomes

Disease Focus

| Disease | Research Focus |
|---------|---------------|
| Alzheimer's Disease | Amyloid therapeutics, biomarkers, clinical trials |
| Parkinson's Disease | Neuroprotection, Lewy body disease, [alpha-synuclein](/proteins/alpha-synuclein) |
| Vascular Cognitive Impairment | Cerebrovascular contributions to dementia |
| TBI-Related Neurodegeneration | Chronic effects of traumatic brain injury |
| Lewy Body Dementia | DLB clinical and basic research |

Key Facilities

Alzheimer's Disease Center

• Memory assessments and clinical evaluations
• Brain imaging studies (MRI, PET)
• Biomarker research
• Clinical trials for new treatments
• Caregiver support and education programs

KU Drug Discovery Lab

• High-throughput compound screening
• In vitro models of neurodegeneration
• Target identification and validation
• Preclinical drug development

Hoglund Biomedical Imaging Center

• 3T and 7T MRI scanners
• PET imaging for amyloid and [tau](/proteins/tau)
• Functional MRI for cognitive studies
• Diffusion tensor imaging for white matter

Landon Center on Aging

• Age-related diseases
• Geriatric medicine
• Cognitive health in aging
• Caregiver support programs

Clinical Programs

• Memory Disorders Clinic: Comprehensive evaluation and treatment for memory disorders
• Movement Disorders Clinic: Parkinson's disease and related conditions
• Clinical Trials Unit: Active enrollment in therapeutic trials
• Caregiver Support Program: Education and resources for families

Training Programs

• PhD programs in Neuroscience, Pharmacology, and Aging Biology
• MD/PhD combined degree programs
• Postdoctoral training in neurodegeneration research
• Clinical fellowship programs in geriatric medicine
• Summer undergraduate research internships

Regional Impact

The University of Kansas serves as the primary research hub for neurodegenerative disease in the Midwest:

Collaborations

KU collaborates with:

• National Institute on Aging (NIA)
• Alzheimer's Association
• Pharmaceutical companies (Biogen, Eli Lilly, Janssen)
• Other Alzheimer's Disease Research Centers
• State of Kansas health agencies

Background

The study of University Of Kansas has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Vascular Dementia](/diseases/vascular-dementia)
• [Lewy Body Dementia](/diseases/lewy-body-dementia)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-hypothesis)
• [Tau Pathology Pathway](/mechanisms/tau-pathology)

External Links

• [KU Official Website](https://www.ku.edu)
• [KU Medical Center](https://www.kumc.edu)
• [Alzheimer's Disease Center](https://www.kumc.edu/school-of-medicine/alzheimer-s-disease-center.html)
• [Hoglund Biomedical Imaging Center](https://www.kumc.edu/hoglund)

References